Diagnostic value of α-enolase expression and serum α-enolase autoantibody levels in lung cancer

Zhang, Lihong; Wang, Hongbin; Dong, Xuejun

doi:10.1590/s1806-37562016000000241

Cited by 23 publications

(27 citation statements)

References 10 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study by our group showed that ENO1 was more highly expressed in lung cancer than in benign tumours; additionally, the expression levels of serum ENO1 antibodies had a diagnostic value in lung cancer ( 19 ). However, the role of ENO1 in the development of liver cancer remains unclear and, to the best of our knowledge, no studies have investigated the expression levels of ENO1 antibodies in the peripheral blood and their diagnostic value in liver cancer.…”

Section: Discussionmentioning

confidence: 94%

α‑enolase is highly expressed in liver cancer and promotes cancer cell invasion and metastasis

Zhang

Yang

et al. 2020

Oncol Lett

Self Cite

View full text Add to dashboard Cite

The expression levels of α-enolase, also known as enolase 1 (ENO1), in liver cancer tissues and the autoantibody levels of ENO1 in the sera of patients with liver cancer were detected to investigate the function of ENO1 in the invasion and metastasis of liver cancer, as well as its clinical diagnostic value. Small interfering RNA (siRNA) was used to disrupt ENO1 gene expression in HepG2 and Huh7 liver cancer cells. The proliferation ability of liver cancer cells was assessed using Cell Counting Kit-8 (CCK-8); the migration ability of liver cancer cells was assessed using scratch tests; and the migration and invasion abilities of liver cancer cells were assessed using Transwell assays. ENO1 expression in liver cancer tissues (43.8%) was significantly higher than that in benign liver lesions (15.2%) (P=0.005). The serum anti-ENO1 antibody levels in the liver cancer group were significantly higher than those in the control and benign liver lesion groups (P<0.001). After ENO1 gene interference, the proliferation, migration and invasion abilities of HepG2 and Huh7 liver cancer cells exhibited different degrees of suppression. The results revealed that ENO1 promotes liver cancer invasion and metastasis; ENO1 plays an important role in liver cancer and can be used as a potential liver cancer-associated marker.

show abstract

Section: Discussionmentioning

confidence: 94%

α‑enolase is highly expressed in liver cancer and promotes cancer cell invasion and metastasis

Zhang

Yang

et al. 2020

Oncol Lett

Self Cite

View full text Add to dashboard Cite

show abstract

“…Decreased invasion in vitro and metastasis in vivo [71] are decreased in stage IV lung and breast cancers [88] , and are lower in stage III/IV than in stage I/II lung cancer patients [89] . By contrast, the presence of anti-a-enolase antibodies in sera from chronic lymphocytic leukaemia (CLL) patients is predictive of a shorter time to first treatment [90] , indicating that the presence of a-enolase antibodies are indicative of a disrupted immune system in CLL.…”

Section: Knockdown In Hec-1b and Ishikawamentioning

confidence: 92%

“…Patients with a higher increase in anti-a-enolase had a lower hazard ratio and better PFS [85] Sera from patients with lung cancer (n = 72), benign lung diseases (n = 69), and healthy individuals (n = 70) Autoantibodies were higher in lung cancer sera compared with sera from normal and benign lung disease patients; Autoantibodies were higher in stage I/II than in stage III/IV [89] Lymphoma…”

Section: Enolase Inhibitors Are Potential Anticancer Agentsmentioning

confidence: 99%

Unlikely role of glycolytic enzyme ��-enolase in cancer metastasis and its potential as a prognostic biomarker

Schofield¹,

Lincz²,

Skelding³

2020

JCMT

View full text Add to dashboard Cite

Reliance on glycolysis for energy production is considered a hallmark of cancer and the glycolytic enzyme a-enolase is overexpressed in a range of cancer types. However, recent studies have revealed that a-enolase is involved in a variety of unrelated physiological processes and can be found in multiple unexpected cellular locations. This review focuses on the unlikely role of a-enolase as an extracellular plasminogen-binding receptor localised to the plasma membrane. Conversion of plasminogen to plasmin on the surface of cancer cells enhances their ability to invade through stroma by activating collagenases and degrading fibrin as well as extracellular matrix proteins. Increased expression of a-enolase is associated with increased migration and invasion of cancer cells, and decreased metastasis-free survival in patients with several cancer types, including non-small cell lung, pancreatic, breast and colorectal cancers. Due to its overexpression in a range of cancer types and multi-functional roles in key areas of tumour metabolism and metastasis, a-enolase may be useful as a universal cancer prognostic biomarker or therapeutic target.

show abstract

“…Enolase (EN), a key glycolytic enzyme contributing to the Warburg effect, is used as a prognostic marker in lung cancer [ 112 ]. Moreover, EN is also an important marker in BC, as was demonstrated by an analysis of 244 BC tissue samples that revealed highly detected EN-1 in ER+ BC.…”

Section: Altered Glucose Metabolism and Anticancer Drug Resistancementioning

confidence: 99%

Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer

Varghese

Samuel

Líšková

et al. 2020

Cancers

126

View full text Add to dashboard Cite

Breast cancer (BC) is the most prevalent cancer in women. BC is heterogeneous, with distinct phenotypical and morphological characteristics. These are based on their gene expression profiles, which divide BC into different subtypes, among which the triple-negative breast cancer (TNBC) subtype is the most aggressive one. The growing interest in tumor metabolism emphasizes the role of altered glucose metabolism in driving cancer progression, response to cancer treatment, and its distinct role in therapy resistance. Alterations in glucose metabolism are characterized by increased uptake of glucose, hyperactivated glycolysis, decreased oxidative phosphorylation (OXPHOS) component, and the accumulation of lactate. These deviations are attributed to the upregulation of key glycolytic enzymes and transporters of the glucose metabolic pathway. Key glycolytic enzymes such as hexokinase, lactate dehydrogenase, and enolase are upregulated, thereby conferring resistance towards drugs such as cisplatin, paclitaxel, tamoxifen, and doxorubicin. Besides, drug efflux and detoxification are two energy-dependent mechanisms contributing to resistance. The emergence of resistance to chemotherapy can occur at an early or later stage of the treatment, thus limiting the success and outcome of the therapy. Therefore, understanding the aberrant glucose metabolism in tumors and its link in conferring therapy resistance is essential. Using combinatory treatment with metabolic inhibitors, for example, 2-deoxy-D-glucose (2-DG) and metformin, showed promising results in countering therapy resistance. Newer drug designs such as drugs conjugated to sugars or peptides that utilize the enhanced expression of tumor cell glucose transporters offer selective and efficient drug delivery to cancer cells with less toxicity to healthy cells. Last but not least, naturally occurring compounds of plants defined as phytochemicals manifest a promising approach for the eradication of cancer cells via suppression of essential enzymes or other compartments associated with glycolysis. Their benefits for human health open new opportunities in therapeutic intervention, either alone or in combination with chemotherapeutic drugs. Importantly, phytochemicals as efficacious instruments of anticancer therapy can suppress events leading to chemoresistance of cancer cells. Here, we review the current knowledge of altered glucose metabolism in contributing to resistance to classical anticancer drugs in BC treatment and various ways to target the aberrant metabolism that will serve as a promising strategy for chemosensitizing tumors and overcoming resistance in BC.

show abstract

Diagnostic value of α-enolase expression and serum α-enolase autoantibody levels in lung cancer

Cited by 23 publications

References 10 publications

α‑enolase is highly expressed in liver cancer and promotes cancer cell invasion and metastasis

α‑enolase is highly expressed in liver cancer and promotes cancer cell invasion and metastasis

Unlikely role of glycolytic enzyme ��-enolase in cancer metastasis and its potential as a prognostic biomarker

Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer

Contact Info

Product

Resources

About

Diagnostic value of α-enolase expression and serum α-enolase autoantibody levels in lung cancer

Cited by 23 publications

References 10 publications

&alpha;‑enolase is highly expressed in liver cancer and promotes cancer cell invasion and metastasis

&alpha;‑enolase is highly expressed in liver cancer and promotes cancer cell invasion and metastasis

Unlikely role of glycolytic enzyme ��-enolase in cancer metastasis and its potential as a prognostic biomarker

Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer

Contact Info

Product

Resources

About

α‑enolase is highly expressed in liver cancer and promotes cancer cell invasion and metastasis

α‑enolase is highly expressed in liver cancer and promotes cancer cell invasion and metastasis